mp.weixin.qq.com·· 10 hours agoScore77
NMPA Accepts Seventh Indication Filing for Kelun-Biotech's sac-TMT Plus Pembrolizumab in First-Line PD-L1-Negative Nonsquamous NSCLC
In brief
China's NMPA has accepted Kelun-Biotech's marketing application for sac-TMT, its seventh accepted indication filing, for use with pembrolizumab as first-line treatment of PD-L1-negative nonsquamous NSCLC.
Source: mp.weixin.qq.com · mp.weixin.qq.com